Nestle India said on Friday that 100 percent of the Maggi instant noodles' samples tested in three laboratories have been cleared and that the noodles are safe for human consumption.
Armed with these reports, the Indian arm of the Swiss multinational food giant plans to resume soon the production of Maggi noodles that were banned last June amid concerns over high lead and monosodium glutamate (MSG) content.
In a statement, Nestle said the results have been received from all three labs mandated by the Bombay High Court to test samples of noodles manufactured by the company.
"All 90 samples, covering six variants, tested by the three laboratories, are clear, with lead much below the permissible limits," the Nestle statement added.
The company assured it would continue to collaborate with the Indian food regulator, Food Safety and Standards Authority of India (FSSAI), and other stakeholders on the issue.
"In compliance with the Bombay High Court orders, we will now commence manufacture and will begin selling only after the newly manufactured products are also cleared by the three designated laboratories. We are committed to reintroduce our Maggi noodles (in the Indian market) at the earliest," Nestle said.
In the past few months, Nestle conducted around 3,500 tests representing 200 million packs in national and international accredited laboratories and all reports were clear.
Besides, tests in several other countries like the US, Britain, Australia and Singapore also found Maggi noodles manufactured in India safe for human consumption.
In June, the FSSAI ordered a nationwide ban on the company's noodles on the ground that these were "unsafe and hazardous" for human consumption due to presence of lead allegedly beyond permissible limits.
The MNC withdrew its instant noodles from the Indian market as a result and moved the Bombay High Court against the FSSAI ban.
A division bench comprising Justices V.M. Kanade and B.P. Colabawalla in August set aside the June 5 order of the FSSAI and also quashed an order of Maharashtra's Food and Drugs Administration banning production and sale of Maggi noodles in India and the state.
The court, however, ordered fresh test on Maggi noodles' samples at three independent labs across India.
Nestle India was directed to send five samples of each variant to accredited labs in Punjab, Hyderabad and Jaipur and asked the labs to give reports within six weeks.
The consumer affairs ministry filed a class action suit against Nestle India, seeking about Rs.640 crore in damages for alleged unfair trade practices, false labelling and misleading advertisements.
It was for the first time that the ministry dragged a company to the National Consumer Disputes Redressal Commission (NCDRC) under the Consumer Protection Act.
However, the apex consumer court on Thursday ordered fresh tests on 13 samples of Maggi noodles from nine batches to determine lead and "MSG stock glutamate" content.
Nestle India on September 30 said that due to the ban, over 9,000 suppliers of Maggi noodles had gone out of business. Over 10,000-12,000 distributors also lost their livelihood. The company said it wished to resolve the matter as soon as possible and was "not interested in delaying it".
Suresh Narayanan, the India chief of the company, earlier said the "focus of the company is to get Nestle back on the shelves" and added that the "controversy had cast a shadow over Nestle's portfolio".
Narayanan told the media that the multinational company was targeting to get the product into the Indian market by the year-end.
Meanwhile, the shares of Nestle India rose by 5.6 percent to Rs.6,555, the biggest gain since August 5. The shares had plunged after FSSAI's recall order which resulted in the company's first ever quarterly loss in more than 15 years.
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.